Outcomes of Elderly Patients Hospitalized with the SARS-CoV-2 Omicron B.1.1.529 Variant: A Systematic Review
暂无分享,去创建一个
C. Cîtu | Cristian-Iulian Oancea | O. Roșca | C. Dumitru | Satish Alambaram | V. Bloancă | Roxana Manuela Fericean | F. Bratosin | Neeharika Gayatri Vasamsetti | Akash Reddy Reddyreddy | Cosmin Cîtu | O. Rosca | Vlad Bloancă
[1] V. Čokić,et al. Three Outbreaks of COVID-19 in a Single Nursing Home over Two Years of the SARS-CoV-2 Pandemic , 2023, Aging and disease.
[2] Wassan Nori,et al. Omicron targets upper airways in pediatrics, elderly and unvaccinated population , 2022, World journal of clinical cases.
[3] Jianquan Li,et al. Paxlovid administration in elderly patient with COVID-19 caused by Omicron BA.2.0: A case report , 2022, Medicine.
[4] N. Chiu,et al. Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic , 2022, Expert review of vaccines.
[5] A. Palamara,et al. Relative effectiveness of a 2nd booster dose of COVID-19 mRNA vaccine up to four months post administration in individuals aged 80 years or more in Italy: A retrospective matched cohort study , 2022, Vaccine.
[6] Xu Dong,et al. Disease Progression of Hospitalized Elderly Patients with Omicron BA.2 Treated with Molnupiravir , 2022, Infectious Diseases and Therapy.
[7] Guangyou Duan,et al. Older age and depressive state are risk factors for re-positivity with SARS-CoV-2 Omicron variant , 2022, Frontiers in Public Health.
[8] O. Launay,et al. COVID-19 Vaccines against Omicron Variant: Real-World Data on Effectiveness , 2022, Viruses.
[9] C. Fan,et al. Identification of CKD, bedridden history and cancer as higher-risk comorbidities and their impact on prognosis of hospitalized Omicron patients: a multi-centre cohort study , 2022, Emerging microbes & infections.
[10] Rosana Pelayo,et al. Decrease in COVID-19 adverse outcomes in adults during the Delta and Omicron SARS-CoV-2 waves, after vaccination in Mexico , 2022, Frontiers in Public Health.
[11] W. Schaffner,et al. COVID-19-Associated Hospitalizations Among Vaccinated and Unvaccinated Adults 18 Years or Older in 13 US States, January 2021 to April 2022 , 2022, JAMA internal medicine.
[12] Chuanlong Zhu,et al. The efficacy of paxlovid in elderly patients infected with SARS-CoV-2 omicron variants: Results of a non-randomized clinical trial , 2022, Frontiers in Medicine.
[13] M. Moret,et al. Retrospective Cohort Study of COVID-19 in Patients of the Brazilian Public Health System with SARS-CoV-2 Omicron Variant Infection , 2022, Vaccines.
[14] P. Austin,et al. Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes , 2022, JAMA network open.
[15] Nathan R. Shively,et al. Description of Hospitalizations due to the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Based on Vaccination Status , 2022, Open forum infectious diseases.
[16] Jiming Zhang,et al. Proportion of asymptomatic infection and nonsevere disease caused by SARS‐CoV‐2 Omicron variant: A systematic review and analysis , 2022, Journal of medical virology.
[17] Jing-wen Ai,et al. Geriatric risk and protective factors for serious COVID-19 outcomes among older adults in Shanghai Omicron wave , 2022, Emerging microbes & infections.
[18] R. Kohli-Seth,et al. The fourth wave: vaccination status and intensive care unit mortality at a large hospital system in New York City , 2022, Acute and critical care.
[19] F. Alhumaydhi,et al. Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2? , 2022, Biomedicine & Pharmacotherapy.
[20] T. Saltykova,et al. Clinical and epidemiological characteristics of hospitalized patients with COVID-19 during different pandemic periods in Moscow , 2022, Journal of microbiology, epidemiology and immunobiology.
[21] N. Pearce,et al. Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil , 2022, Nature Communications.
[22] R. Bellomo,et al. Clinical Characteristics and Outcomes of Critically Ill Patients with 1, 2 and 3 doses of Vaccination against COVID‐19 in Australia , 2022, Internal medicine journal.
[23] Jue Liu,et al. The Association between Risk Perception and Hesitancy toward the Booster Dose of COVID-19 Vaccine among People Aged 60 Years and Older in China , 2022, Vaccines.
[24] E. Leung,et al. SARS-CoV-2 Omicron: Light at the End of the Long Pandemic Tunnel or Another False Dawn for Immunodeficient Patients? , 2022, The Journal of Allergy and Clinical Immunology: In Practice.
[25] R. Brondeel,et al. Clinical Severity of SARS-CoV-2 Omicron Variant Compared with Delta among Hospitalized COVID-19 Patients in Belgium during Autumn and Winter Season 2021–2022 , 2022, Viruses.
[26] P. Cheung,et al. Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis , 2022, BMJ.
[27] A. Nouvenne,et al. Defining SARS-CoV-2 breakthrough infection needing hospitalization in mass vaccination era: from disease-centered to patient-centered care , 2022, Acta bio-medica : Atenei Parmensis.
[28] E. Orenbuch-Harroch,et al. Hospitalized patients with severe COVID-19 during the Omicron wave in Israel – benefits of a fourth vaccine dose , 2022, medRxiv.
[29] J. L. Bernal,et al. Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study , 2022, Nature Communications.
[30] U. Malmqvist,et al. Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities – surveillance results from southern Sweden, July 2021 to January 2022 , 2022, medRxiv.
[31] S. Zeger,et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression , 2022, The Lancet.
[32] Md. Rabiul Islam,et al. New Coronavirus Variants are Creating More Challenges to Global Healthcare System: A Brief Report on the Current Knowledge , 2022, Clinical pathology.
[33] R. Mukherjee,et al. Why are some coronavirus variants more infectious? , 2021, Journal of Biosciences.
[34] Michael J. Hogan,et al. mRNA Vaccines in the COVID-19 Pandemic and Beyond. , 2021, Annual review of medicine.
[35] K. Hirayama,et al. Quality assessment tools used in systematic reviews of in vitro studies: A systematic review , 2021, BMC Medical Research Methodology.
[36] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.
[37] C. Dolea,et al. World Health Organization , 1949, International Organization.